PT  - JOURNAL ARTICLE
AU  - MAEKURA, TOSHIYA
AU  - NAITO, MAIKO
AU  - TAHARA, MASAHIRO
AU  - IKEGAMI, NAOYA
AU  - KIMURA, YOHEI
AU  - SONOBE, SHOKO
AU  - KOBAYASHI, TAKEHIKO
AU  - TSUJI, TAISUKE
AU  - MINOMO, SHOJIRO
AU  - TAMIYA, AKIHIRO
AU  - ATAGI, SHINJI
TI  - Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
DP  - 2017 Sep 01
TA  - In Vivo
PG  - 1035--1039
VI  - 31
IP  - 5
4099  - http://iv.iiarjournals.org/content/31/5/1035.short
4100  - http://iv.iiarjournals.org/content/31/5/1035.full
SO  - In Vivo2017 Sep 01; 31
AB  - Background/Aim: Although immune checkpoint inhibitors play an important role in the therapy of lung cancer, they are associated with various immune-related adverse events and predictive factors of them are unclear. In this study, we investigated predictive factors of nivolumab-induced hypothyroidism which is one of the adverse events in patients with lung cancer. Patients and Methods: Patients with non-small-cell lung cancer who were administered nivolumab at our hospital between December 2015 and May 2016 were retrospectively enrolled. The thyroid-stimulating hormone, free triiodothyronine, free thyroxine, thyroid peroxidase (TPO) antibody, and thyroglobulin antibody levels of each patient were analyzed. Results: Of the 64 patients enrolled, 5 (7.8%) developed hypothyroidism after treatment with nivolumab. The TPO and thyroglobulin antibodies were significantly positive in patients who developed primary hypothyroidism. Conclusion: TPO and thyroglobulin antibody levels at baseline may be predictive of hypothyroidism.